Joshua P. Plotnik
AbbVie (United States)(US)
Publications by Year
Research Areas
Protein Degradation and Inhibitors, Multiple Myeloma Research and Treatments, Chromatin Remodeling and Cancer, NF-κB Signaling Pathways, Ubiquitin and proteasome pathways
Most-Cited Works
- → Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer(2020)393 cited
- → ETS1 is a genome-wide effector of RAS/ERK signaling in epithelial cells(2014)122 cited
- → An Interaction with Ewing’s Sarcoma Breakpoint Protein EWS Defines a Specific Oncogenic Mechanism of ETS Factors Rearranged in Prostate Cancer(2016)52 cited
- → ETS1 induction by the microenvironment promotes ovarian cancer metastasis through focal adhesion kinase(2017)51 cited
- → Selective Inhibition of the Second Bromodomain of BET Family Proteins Results in Robust Antitumor Activity in Preclinical Models of Acute Myeloid Leukemia(2021)33 cited
- → Extracellular Signal-Regulated Kinase Signaling Regulates the Opposing Roles of JUN Family Transcription Factors at ETS/AP-1 Sites and in Cell Migration(2014)31 cited
- → Interaction with ZMYND11 mediates opposing roles of Ras-responsive transcription factors ETS1 and ETS2(2017)23 cited
- → Synthetic lethality of mRNA quality control complexes in cancer(2025)17 cited
- → Toll-like receptor 4 signaling activates ERG function in prostate cancer and provides a therapeutic target(2021)15 cited